Comparable stake leader
Cecilia Jones
SEC ownership of LogicBio Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001664106.
Disclosed value leader
—
Comparable rows
0/2
Latest evidence
01 Mar 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Cecilia Jones
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
01 Mar 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001664106
- Issuer location
- Lexington, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LogicBio Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cecilia Jones
Disclosed value leader
—
Comparable rows
0/2
Latest evidence
01 Mar 2022
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
2 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Cecilia Jones's linked filing trail.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cecilia Jones |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
112,000 shares
|
— | 01 Mar 2022 |
| Andrea Paul |
3/4/5
General Counsel and Secretary
|
—
class O/S missing
|
—
80,000 shares
|
— | 01 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to LogicBio Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Daniel Gruskin
Net 12M change
$0
Latest report
16 Nov 2022
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Daniel Gruskin | Chief Medical Officer | Mixed | 16 Nov 2022 | |||
| Jeff Goater | Director | Mixed | 16 Nov 2022 | |||
| MOSCICKI RICHARD A | Director | Mixed | 16 Nov 2022 | |||
| Cecilia Jones | Chief Financial Officer | Mixed | 01 Mar 2022 | |||
| Leon Chen | Director | Mixed | 16 Nov 2022 | |||
| Mark J. Enyedy | Director | Mixed | 16 Nov 2022 | |||
| Mark A. Kay | Director | Mixed | 16 Nov 2022 | |||
| Daphne Karydas | Director | Mixed | 16 Nov 2022 | |||
| Susan Kahn | Director | Mixed | 16 Nov 2022 | |||
| Mariana Nacht | Chief Scientific Officer | Mixed | 16 Nov 2022 | |||
| Michael S. Wyzga | Director | Mixed | 16 Nov 2022 | |||
| Frederic Chereau | President, CEO, Director | Mixed | 16 Nov 2022 | |||
| Andrea Paul | General Counsel and Secretary | Mixed | 01 Mar 2022 | |||
| Joshua Blacher | Interim CFO | Mixed | 23 Sep 2022 |
Recent insider transactions for LogicBio Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.